Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Avadel Pharmaceuticals (Nasdaq: AVDL) announced on October 13, 2025 that its Compensation Committee approved inducement option awards for seven new employees totaling 161,600 ordinary shares under the company's 2021 Inducement Plan.

The non-statutory options carry a 10-year term and vest over four years with 25% vesting after one year and 25% on each of the second, third, and fourth anniversaries of each employee's start date. Awards are granted as inducements under Nasdaq Listing Rule 5635(c)(4) and are subject to the 2021 Inducement Plan and individual award agreements.

DUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to seven (7) new employees to purchase 161,600 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee’s respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com. 

Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696

Media Contact:
Alyssa Ramirez
Real Chemistry
aramirez@realchemistry.com

FAQ

What did Avadel (AVDL) announce on October 13, 2025 regarding employee stock options?

Avadel announced grants of non-statutory options for seven new employees totaling 161,600 ordinary shares under its 2021 Inducement Plan.

How long is the term for Avadel's inducement options (AVDL) granted October 13, 2025?

The options have a 10-year term from grant.

What is the vesting schedule for Avadel (AVDL) inducement awards dated October 13, 2025?

Options vest over four years: 25% at the one-year anniversary and 25% on each of years two, three, and four.

Under which Nasdaq rule were Avadel's (AVDL) inducement awards approved?

The awards were granted as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement option grants from Avadel (AVDL) on October 13, 2025?

Seven new employees received the inducement option grants.

Are Avadel's (AVDL) inducement options subject to plan terms and individual agreements?

Yes. The options are subject to the 2021 Inducement Plan and individual award agreement terms and conditions.